CU20100233A7 - Combinación veterinaria para el control de infecciones virales en la acuicultura - Google Patents

Combinación veterinaria para el control de infecciones virales en la acuicultura

Info

Publication number
CU20100233A7
CU20100233A7 CU20100233A CU20100233A CU20100233A7 CU 20100233 A7 CU20100233 A7 CU 20100233A7 CU 20100233 A CU20100233 A CU 20100233A CU 20100233 A CU20100233 A CU 20100233A CU 20100233 A7 CU20100233 A7 CU 20100233A7
Authority
CU
Cuba
Prior art keywords
organisms
infected
pacap
combination
antiviral
Prior art date
Application number
CU20100233A
Other languages
English (en)
Other versions
CU23975B1 (es
Inventor
García Mario Pablo Estrada
González Juana María Lugo
González Yamila Carpio
Piñeiro Carolina Tafalla
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU20100233A priority Critical patent/CU20100233A7/es
Priority to JP2013541202A priority patent/JP5997702B2/ja
Priority to BR112013013526A priority patent/BR112013013526B1/pt
Priority to CA2819206A priority patent/CA2819206C/en
Priority to CN201180064517.1A priority patent/CN103298452B/zh
Priority to MYPI2013700897A priority patent/MY165435A/en
Priority to PH1/2013/501232A priority patent/PH12013501232A1/en
Priority to PCT/CU2011/000008 priority patent/WO2012072055A1/es
Priority to PT118078542T priority patent/PT2647369T/pt
Priority to KR1020137017000A priority patent/KR101838721B1/ko
Priority to ES11807854.2T priority patent/ES2621332T3/es
Priority to EP11807854.2A priority patent/EP2647369B1/en
Priority to US13/989,921 priority patent/US9119830B2/en
Priority to AU2011335519A priority patent/AU2011335519B2/en
Priority to MX2013006217A priority patent/MX347844B/es
Priority to RU2013129830/13A priority patent/RU2567802C2/ru
Priority to SG2013051289A priority patent/SG191823A1/en
Priority to ARP110104456 priority patent/AR084049A1/es
Publication of CU20100233A7 publication Critical patent/CU20100233A7/es
Priority to ZA2013/04025A priority patent/ZA201304025B/en
Priority to CL2013001561A priority patent/CL2013001561A1/es
Publication of CU23975B1 publication Critical patent/CU23975B1/es
Priority to US14/839,114 priority patent/US9603900B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Fodder In General (AREA)

Abstract

La presente invención está relacionada con una combinación veterinaria que comprende el polipéptido activador de la adenilato ciclasa de pituitaria (PACAP) y un antiviral, seleccionado entre rivabirina y amantidina, para el tratamiento de infecciones virales y enfermedades infecciosas causadas por virus, en organismos acuáticos. El PACAP combinado con dichas moléculas antivirales, administrado por vía oral, inyección o por baños de inmersión, demuestra su efectividad al aumentar la sobrevida de peces o crustáceos infectados por virus. Además, tras la aplicación de dicha combinación se observa que el peso corporal de estos organismos se mantiene igual o aumenta, en comparación con el de los organismos infectados y no tratados con dichas preparaciones. Mediante reverso transcripción-reacción en cadena de la polimerasa de tejidos y órganos susceptibles a la infección viral se demuestra que las combinaciones que contienen PACAP y las moléculas antivirales ribavirina y amantidina, disminuyen la carga viral en los organismos infectados.
CU20100233A 2010-01-12 2010-12-01 Combinación veterinaria para el control de infecciones virales en la acuicultura CU20100233A7 (es)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CU20100233A CU20100233A7 (es) 2010-12-01 2010-12-01 Combinación veterinaria para el control de infecciones virales en la acuicultura
US13/989,921 US9119830B2 (en) 2010-01-12 2011-11-30 Use of PACAP for the treatment of viral infections in aquatic organisms
EP11807854.2A EP2647369B1 (en) 2010-12-01 2011-11-30 Pacap for the treatment of viral infections in aquatic organisms
CA2819206A CA2819206C (en) 2010-12-01 2011-11-30 Use of pacap for treating viral infections in aquatic organisms
CN201180064517.1A CN103298452B (zh) 2010-12-01 2011-11-30 Pacap用于在水生生物中治疗病毒感染的用途
MYPI2013700897A MY165435A (en) 2010-12-01 2011-11-30 Use of pacap for the treatment of viral infections in aquatic organisms
PH1/2013/501232A PH12013501232A1 (en) 2010-12-01 2011-11-30 Use of pacap for treating viral infections in aquatic organisms
PCT/CU2011/000008 WO2012072055A1 (es) 2010-12-01 2011-11-30 Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos
PT118078542T PT2647369T (pt) 2010-12-01 2011-11-30 Pacap para o tratamento de infeções virais em organismos aquáticos
KR1020137017000A KR101838721B1 (ko) 2010-12-01 2011-11-30 수중 생물에서 바이러스 감염을 치료하기 위한 pacap의 용도
AU2011335519A AU2011335519B2 (en) 2010-12-01 2011-11-30 Use of PACAP for treating viral infections in aquatic organisms
JP2013541202A JP5997702B2 (ja) 2010-12-01 2011-11-30 水生生物におけるウイルス感染を処置するためのｐａｃａｐの使用
BR112013013526A BR112013013526B1 (pt) 2010-12-01 2011-11-30 uso de pacap para o tratamento de infecções virais em organismos aquáticos, e combinação veterinária
ES11807854.2T ES2621332T3 (es) 2010-12-01 2011-11-30 PACAP para el tratamiento de infecciones virales en organismos acuáticos
MX2013006217A MX347844B (es) 2010-12-01 2011-11-30 Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos.
RU2013129830/13A RU2567802C2 (ru) 2010-12-01 2011-11-30 Применение расар для лечения вирусных инфекций у водных организмов
SG2013051289A SG191823A1 (en) 2010-12-01 2011-11-30 Use of pacap for treating viral infections in aquatic organisms
ARP110104456 AR084049A1 (es) 2010-12-01 2011-11-30 Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos
ZA2013/04025A ZA201304025B (en) 2010-12-01 2013-05-31 Use of pacap for treating viral infections in aquatic organisms
CL2013001561A CL2013001561A1 (es) 2010-12-01 2013-05-31 Composicion que comprende al polipeptido activador de la adenilato ciclasa de pituitaria (pacap); combinacion veterinaria que comprende al pacap y una molecula antiviral; y uso del pacap para el tratamiento de enfermedades infecciosas causadas por virus en organismos acuaticos.
US14/839,114 US9603900B2 (en) 2010-12-01 2015-08-28 Use of PACAP for the treatment of viral infections in aquatic organisms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20100233A CU20100233A7 (es) 2010-12-01 2010-12-01 Combinación veterinaria para el control de infecciones virales en la acuicultura

Publications (2)

Publication Number Publication Date
CU20100233A7 true CU20100233A7 (es) 2012-10-15
CU23975B1 CU23975B1 (es) 2014-01-29

Family

ID=45476244

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20100233A CU20100233A7 (es) 2010-01-12 2010-12-01 Combinación veterinaria para el control de infecciones virales en la acuicultura

Country Status (20)

Country Link
US (2) US9119830B2 (es)
EP (1) EP2647369B1 (es)
JP (1) JP5997702B2 (es)
KR (1) KR101838721B1 (es)
CN (1) CN103298452B (es)
AR (1) AR084049A1 (es)
AU (1) AU2011335519B2 (es)
BR (1) BR112013013526B1 (es)
CA (1) CA2819206C (es)
CL (1) CL2013001561A1 (es)
CU (1) CU20100233A7 (es)
ES (1) ES2621332T3 (es)
MX (1) MX347844B (es)
MY (1) MY165435A (es)
PH (1) PH12013501232A1 (es)
PT (1) PT2647369T (es)
RU (1) RU2567802C2 (es)
SG (1) SG191823A1 (es)
WO (1) WO2012072055A1 (es)
ZA (1) ZA201304025B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105755014B (zh) * 2016-03-23 2019-03-19 中国科学院水生生物研究所 CaHV-TNFR特异基因及应用
CN117281905A (zh) * 2023-09-14 2023-12-26 中国水产科学研究院黑龙江水产研究所 磷脂酶a2作为靶点在防治传染性造血器官坏死病毒感染中的应用
CN118592401B (zh) * 2024-05-15 2025-03-18 中国科学院水生生物研究所 一种草鱼gcrv感染模型的建立方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695954A (en) * 1993-05-14 1997-12-09 University Of Victoria Innovation & Development Corporation DNA encoding two fish neuropeptides
CU23557A1 (es) 2005-11-22 2010-07-20 Ct Ingenieria Genetica Biotech Neuropéptidos para el cultivo de organismos acuáticos

Also Published As

Publication number Publication date
PT2647369T (pt) 2017-04-11
AR084049A1 (es) 2013-04-17
MX2013006217A (es) 2013-07-15
US20140087998A1 (en) 2014-03-27
US9603900B2 (en) 2017-03-28
US9119830B2 (en) 2015-09-01
EP2647369A1 (en) 2013-10-09
CA2819206C (en) 2018-07-10
EP2647369B1 (en) 2017-01-25
BR112013013526A2 (pt) 2016-10-18
SG191823A1 (en) 2013-08-30
AU2011335519B2 (en) 2016-09-22
MX347844B (es) 2017-05-16
RU2567802C2 (ru) 2015-11-10
CA2819206A1 (en) 2012-06-07
KR101838721B1 (ko) 2018-03-14
CN103298452A (zh) 2013-09-11
CU23975B1 (es) 2014-01-29
ES2621332T3 (es) 2017-07-03
CN103298452B (zh) 2016-08-10
RU2013129830A (ru) 2015-01-10
MY165435A (en) 2018-03-22
CL2013001561A1 (es) 2014-03-21
JP2013544262A (ja) 2013-12-12
PH12013501232A1 (en) 2013-08-05
BR112013013526B1 (pt) 2020-04-07
JP5997702B2 (ja) 2016-09-28
US20160030519A1 (en) 2016-02-04
ZA201304025B (en) 2014-02-26
WO2012072055A1 (es) 2012-06-07
AU2011335519A1 (en) 2013-06-20
KR20140031840A (ko) 2014-03-13

Similar Documents

Publication Publication Date Title
Espín-Palazón et al. TNFα impairs rhabdoviral clearance by inhibiting the host autophagic antiviral response
AR084393A1 (es) Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
EA201490837A1 (ru) Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
Baruah et al. Reactive oxygen species generated by a heat shock protein (Hsp) inducing product contributes to Hsp70 production and Hsp70-mediated protective immunity in Artemia franciscana against pathogenic vibrios
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
Liu et al. Antiviral efficiency of a coumarin derivative on spring viremia of carp virus in vivo
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
Huang et al. Research on the indirect antiviral function of medicinal plant ingredient quercetin against grouper iridovirus infection
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
EA201991174A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
CY1111526T1 (el) Αναστολεις κυκλοπροπυλ συντηγμενης ινδολοβενζαζεπινης της ns5b του hcv
Shao et al. Up-regulation of nuclear factor E2-related factor 2 (Nrf2) represses the replication of SVCV
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
RU2013119607A (ru) Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
Rahman et al. The effect of raising water temperature to 33 C in Penaeus vannamei juveniles at different stages of infection with white spot syndrome virus (WSSV)
CU20100233A7 (es) Combinación veterinaria para el control de infecciones virales en la acuicultura
Shan et al. A novel antiviral coumarin derivative as a potential agent against WSSV infection in shrimp seedling culture
AR082442A1 (es) Metodo para mejorar la eficiencia de alimentacion, mejorar el aumento o reducir la mortalidad en un animal y composicion correspondiente
EA201001835A1 (ru) Противовирусные соли
BR112017001589A2 (pt) peptídeos marinhos e nucleotídeos de peixe, composições e usos dos mesmos para reduzir a glicose no sangue
CU24075B1 (es) Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
TH162735A (th) การใช้ pacap เพื่อรักษาการติดเชื้อไวรัสในสิ่งมีชีวิตในน้ำ

Legal Events

Date Code Title Description
FG Grant of patent